French pharmaceutical giant shaping global health since 1973
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
President Trump has signed an executive order directing federal health officials to cut the federal recommended childhood vaccine list, to split the combined MMR vaccine into separate measles, mumps and rubella doses once single‑disease products are available, and to space routine immunisations across separate medical visits. Public health groups and drugmakers have said the changes lack scientific support and will increase missed vaccinations during a major U.S. measles outbreak.
Major US medical societies have issued unified guidance this week for flu, COVID-19 and RSV vaccines after the CDC’s advisory process has been disrupted. Updated COVID shots have FDA approval and manufacturers are shipping doses, but legal and policy disputes over federal recommendations continue to leave states and insurers uncertain about timing and coverage.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Arm Holdings chief executive Rene Haas says AI could one day help cure cancer, but the path is constrained by chip shortages and a demand surge for AI data centres. Multiple outlets report Haas’s remarks, framing a broaderAI-driven push in healthcare and manufacturing, while flagging supply constraints and broader market excitement.
Flu vaccines are underway and updated COVID-19 shots are arriving nationwide after FDA approval. RSV remains a threat, prompting guidance from medical societies as Trump health officials rethink autumn vaccine policies. An advisory panel remains in a legal dispute, while doctors push clear, science-based guidance. Older adults and high-risk groups are urged to vaccinate, with a new mRNA flu shot showing improved effectiveness.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Volunteers and international rabbis have been detained by Israeli forces while harvesting olives near Nahalin, west of Bethlehem. Brad Lander, a Democratic congressional nominee from New York, has been released with a warning; dozens of other volunteers, including US, British and Canadian citizens, have remained in custody. Israeli authorities say the harvest lacked prior security coordination.
The UN and WMO warn that the current El Niño event could be unprecedented in strength, peaking late 2026, with impacts that will be felt long afterward. Sea-surface temperatures may rise to 3.8°C above average between November 2026 and January 2027, triggering far-reaching weather shifts and humanitarian strain across regions.
France’s Ligue 1 clash between Paris Saint‑Germain and Olympique Lyonnais has been postponed from Sunday to Monday due to police prohibitions tied to mass protests. The match will now kick off at 20:30 local time at Parc des Princes, as authorities plan a major security operation alongside an NFL game in Paris.